Publications by authors named "Rodrigo de Nicolas"
Article Synopsis
- Many cases of erythrocytosis and thrombocytosis are still classified as "idiopathic" due to factors like lack of secondary causes or inconclusive tests, despite advancements in genetic testing.
- Next-generation sequencing (NGS) was reviewed in 175 patients, leading to diagnoses in a small number: 5.1% for polycythaemia vera and 6.8% for familial erythrocytosis, with low EPO levels and family history being predictors.
- The study found a higher success rate in diagnosing thrombocytosis cases, with 25.9% identified as having essential thrombocythemia, but overall, the low variant detection rate suggests the need for comprehensive initial screening before using N
Background: Lymphoid neoplasms treatment has recently been renewed to increase antitumor efficacy and conventional chemotherapies toxicities. Limited data have been published about the infection risk associated with these new drugs, therefore this study analyzes the infectious complications in patients with lymphoproliferative diseases (LPD) treated with monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib and acalabrutinib), PI3K inhibitors (idelalisib) and BCL2 inhibitors (venetoclax).
Methods: Multicenter retrospective study of 458 LPD patients treated with targeted therapies in real-life setting, in 18 Spanish institutions, from the time of their commercial availability to August 2020.
BCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq signature in a series of patients with BCP-ALL. To this end, we developed and tested an RNA-Seq custom panel of 42 genes related to a BCR-ABL1-like signature in a cohort of 100 patients with BCP-ALL and treated with risk-adapted ALL trials.
View Article and Find Full Text PDF